Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.
Sihuan Pharmaceutical announced that preliminary data from the Phase 1b FORTRESS trial of NG-350A in patients with mismatch repair-proficient locally advanced rectal cancer were presented at the 2026 AACR meeting. NG-350A, combined with standard chemoradiotherapy, achieved a 50% composite clinical response rate in the first 10 patients over 12 weeks, roughly double the typical 25% rate seen with chemoradiotherapy alone.
The early results showed no serious adverse events or new safety signals linked to NG-350A, underscoring a favorable safety and tolerability profile in this setting. The findings suggest NG-350A could enhance outcomes for high-risk rectal cancer patients and strengthen Sihuan’s and Xuanzhu’s position in advanced colorectal cancer treatment as they push forward with clinical trial applications in mainland China.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group is a Hong Kong-listed pharmaceutical company with a focus on innovative oncology therapies through its subsidiary Xuanzhu Biopharmaceutical. Xuanzhu holds exclusive Greater China rights to NG-350A, an oncolytic immunotherapy sourced from U.S.-based Akamis Bio, and is advancing its clinical development and commercialization in the region.
YTD Price Performance: 17.89%
Average Trading Volume: 35,639,862
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.53B
Learn more about 0460 stock on TipRanks’ Stock Analysis page.